Sugi Predict

Sugi Predict / Targets / PIR

PIR

Pirin · O00625 · PIR on Sugi Atlas →

3,699 patent compounds predicted against PIR, 2,915 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL1000348 SCHEMBL1000348 0.42 4/20
Plx-4720 Plx-4720 (SCHEMBL133733) 1.00 1/20
SCHEMBL298760 SCHEMBL298760 0.90 1/20
SCHEMBL298198 SCHEMBL298198 0.88 1/20
SCHEMBL298282 SCHEMBL298282 0.84 1/20
SCHEMBL298349 SCHEMBL298349 0.83 1/20
SCHEMBL299672 SCHEMBL299672 0.83 1/20
Vemurafenib Vemurafenib (SCHEMBL298931) 0.82 1/20
SCHEMBL294160 SCHEMBL294160 0.82 1/20
SCHEMBL297768 SCHEMBL297768 0.80 1/20
SCHEMBL298366 SCHEMBL298366 0.80 1/20
SCHEMBL298957 SCHEMBL298957 0.80 1/20
SCHEMBL299509 SCHEMBL299509 0.80 1/20
SCHEMBL298900 SCHEMBL298900 0.80 1/20
SCHEMBL293053 SCHEMBL293053 0.80 1/20
SCHEMBL296824 SCHEMBL296824 0.79 1/20
SCHEMBL297725 SCHEMBL297725 0.79 1/20
SCHEMBL298479 SCHEMBL298479 0.79 1/20
SCHEMBL299189 SCHEMBL299189 0.79 1/20
SCHEMBL298433 SCHEMBL298433 0.79 1/20

Clinical trials — most relevant to PIR by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Efficacy and Safety of Pirfenidone in CTD-ILD PHASE4UNKNOWN
Influence of Genotype of CYP2C9 on Clinical Efficacy and Pharmacokinetics of Piroxicam After Lower Third Molar Surgery PHASE4COMPLETED
Effect of Pirfenidone on TA Fibrosis PHASE4NOT_YET_RECRUITING
Piromelatine 20 mg in Participants With Mild Dementia Due to Alzheimer's Disease PHASE2/PHASE3ACTIVE_NOT_RECRUITING
European Trial of Pirfenidone in BOS, A European Multi-center Study PHASE2/PHASE3COMPLETED
Efficacy and Safety of Pirfenidone in Patient With Systemic Sclerosis-associated Interstitial Lung Disease PHASE3UNKNOWN
Pirfenidone Capsules in the Treatment of Radiation-induced Lung Injury With or Without Immune Pneumonia PHASE2/PHASE3RECRUITING
Prolonged Release Pirfenidone Versus Placebo in Compensated Cirrhosis. PHASE2COMPLETED
Piritrexim in Treating Patients With Advanced Cancer of the Urinary Tract PHASE2COMPLETED
Pirfenidone in Children and Young Adults With Neurofibromatosis Type I and Progressive Plexiform Neurofibromas PHASE2COMPLETED
PirfenidoneVsPlacebo as Prophylaxis Against Acute Radiation-induced Lung Injury Following HFRT in Breast Cancer Patients PHASE2RECRUITING
Safety and Efficacy of Piromelatine in Mild Alzheimer's Disease Patients (ReCOGNITION) PHASE2COMPLETED
Trial of Pirfenidone to Prevent Progression in Chronic Kidney Disease PHASE2UNKNOWN
A Clinical Study Evaluating Efficacy of Pirepemat on Falls Frequency in Patients with Parkinson's Disease (PD) PHASE2COMPLETED
Pirfenidone to Treat Kidney Disease (Focal Segmental Glomerulosclerosis) PHASE2COMPLETED
Evaluation of Pirfenidone as a Novel Therapeutic Strategy Against Recurrent Acute Pancreatitis. PHASE2RECRUITING
PI-88 in Treating Patients With an Advanced Malignancy (Cancer) or Stage IV Melanoma PHASE1/PHASE2COMPLETED
A Study in People With Idiopathic Pulmonary Fibrosis to Test Whether Pirfenidone Influences the Amount of BI 1015550 in the Blood PHASE2RECRUITING
A Study to Test How Taking BI 1015550 for 12 Weeks Affects Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF) PHASE2COMPLETED
Pirfenidone Capsule in Patients With Chronic Kidney Disease G2 and G3a Study on Safety and Pharmacokinetics PHASE1UNKNOWN
A Phase 1b Study of IV PRM151 in Patients With Idiopathic Pulmonary Fibrosis (IPF) PHASE1COMPLETED
Study in Healthy Adults to Quantify Lung Deposition and Distribution of Radio-labelled S-770108 Inhalation Powder Formulation Delivered by a Novel Inhaler Device PHASE1COMPLETED
A Study of Two Different Formulations of Pirtobrutinib (LOXO-305) In Healthy Participants PHASE1COMPLETED
A Bioequivalence Study Comparing Pirfenidone Tablet and Capsule Dosage Forms in Healthy Adult Participants PHASE1COMPLETED
SEDPARK1: Safety and Efficacy Study With the Non-ergot Dopamine-agonist Piribedil in Parkinson's Disease nanCOMPLETED
Clinical Study on the Application of PET Probes Targeting DDR2 in the Diagnosis of Interstitial Lung Disease With Cognitive Impairment nanNOT_YET_RECRUITING
Monitoring Brain Activity in Human Brain Injury nanUNKNOWN
Effect of the Combination of Pterostilbene Cocrystal With Silybin and Nicotinamide Riboside on Exercise-Induced Oxidative Stress nanRECRUITING
Pirfenidone in Treating Patients With Fibrosis Caused by Radiation Therapy for Cancer nanCOMPLETED
Evaluation of Long-Term Safety of Pirfenidone (Esbriet) in Participants With Idiopathic Pulmonary Fibrosis (IPF) nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a PIR binder may also engage these)

ProteinNameSimilarity
Q5M827 — 1.000 Q5M827 →
Q9D711 — 1.000 Q9D711 →
Q9SEE4 — 0.982 Q9SEE4 →
Q9LX49 — 0.970 Q9LX49 →
Q9ZW82 — 0.968 Q9ZW82 →
Q9I163 — 0.967 Q9I163 →
Q9LPS9 — 0.962 Q9LPS9 →
Q66WM4 — 0.957 Q66WM4 →
Q924M7 — 0.954 Q924M7 →
Q3SZI0 — 0.954 Q3SZI0 →
Q68FX1 — 0.953 Q68FX1 →
Q29554 — 0.952 Q29554 →
O08709 — 0.951 O08709 →
Q8HXX2 — 0.950 Q8HXX2 →
P93732 — 0.950 P93732 →
D1ZQL9 — 0.950 D1ZQL9 →
Q2PFL9 — 0.950 Q2PFL9 →
A6SDE9 — 0.949 A6SDE9 →
A7UWH7 — 0.949 A7UWH7 →
Q9VLS9 — 0.949 Q9VLS9 →
Q0U6G5 — 0.948 Q0U6G5 →
MPI Mannose-6-phosphate isomerase 0.948 landscape →
O77834 — 0.948 O77834 →
A5A6K3 — 0.948 A5A6K3 →
O04226 — 0.948 O04226 →
P54887 — 0.948 P54887 →
Q6NYF0 — 0.948 Q6NYF0 →
Q96WX8 — 0.948 Q96WX8 →
P29951 — 0.947 P29951 →
Q96480 — 0.947 Q96480 →